IMM.AX
Price:
$0.325
Market Cap:
$473.07M
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the ...[Read more]
Industry
Biotechnology
IPO Date
1988-06-30
Stock Exchange
ASX
Ticker
IMM.AX
According to Immutep Limited’s latest financial reports and current stock price. The company's current ROE is -34.61%. This represents a change of 237.54% compared to the average of -10.25% of the last 4 quarters.
The mean historical ROE of Immutep Limited over the last ten years is -64.97%. The current -34.61% ROE has changed -46.73% with respect to the historical average. Over the past ten years (40 quarters), IMM.AX's ROE was at its highest in in the June 2012 quarter at 0%. The ROE was at its lowest in in the December 2015 quarter at -138.26%.
Average
-64.97%
Median
-40.63%
Minimum
-175.59%
Maximum
-29.23%
Discovering the peaks and valleys of Immutep Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 120.49%
Maximum Annual ROE = -29.23%
Minimum Annual Increase = -79.89%
Minimum Annual ROE = -175.59%
Year | ROE | Change |
---|---|---|
2023 | -29.23% | -14.62% |
2022 | -34.24% | -16.10% |
2021 | -40.81% | 0.90% |
2020 | -40.45% | -39.38% |
2019 | -66.72% | 75.46% |
2018 | -38.02% | 7.70% |
2017 | -35.30% | -79.89% |
2016 | -175.59% | 34.84% |
2015 | -130.22% | 120.49% |
2014 | -59.06% | 13.46% |
The current ROE of Immutep Limited (IMM.AX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-34.76%
5-year avg
-42.29%
10-year avg
-64.97%
Immutep Limited’s ROE is greater than Imugene Limited (-95.62%), less than Telix Pharmaceuticals Limited (11.29%), greater than Kazia Therapeutics Limited (-2633.62%), less than Opthea Limited (520.65%), greater than Prescient Therapeutics Limited (-40.50%),
Company | ROE | Market cap |
---|---|---|
-95.62% | $319.85M | |
11.29% | $8.03B | |
-2633.62% | $18.91M | |
520.65% | $923.44M | |
-40.50% | $38.66M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immutep Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immutep Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Immutep Limited's ROE?
How is the ROE calculated for Immutep Limited (IMM.AX)?
What is the highest ROE for Immutep Limited (IMM.AX)?
What is the 3-year average ROE for Immutep Limited (IMM.AX)?
What is the 5-year average ROE for Immutep Limited (IMM.AX)?
How does the current ROE for Immutep Limited (IMM.AX) compare to its historical average?